Clinical trials: Metastatic Bladder Cancer
Locally Advanced or Metastatic Urothelial Bladder Cancer
Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer
This was a single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of the anti- programmed cell death-1(PD-1) monoclonal antibody BGB-A317 in participants with PD-L1+, locally advanced or metastatic Urothelial…
- Trial name
- NCT04004221
- Testing
- Tislelizumab
- Where
- 27 sites in China, South Korea
- Volunteers
- 113 people
- Sponsor
- BeiGene